Notice2022-28404
Prospective Grant of an Exclusive Patent License: Development and Commercialization of Natural Killer Cell Therapies for Cancer
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
December 30, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Replay Holdings LLC ("Replay") located in San Diego, California.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 250 (Friday, December 30, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 250 (Friday, December 30, 2022)]
[Notices]
[Pages 80556-80565]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-28404]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Development and
Commercialization of Natural Killer Cell Therapies for Cancer
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an Exclusive Patent License to practice the
inventions embodied in the Patents and Patent Applications listed in
the Supplementary Information section of this notice to Replay Holdings
LLC (``Replay'') located in San Diego, California.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before January 17, 2023 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an Exclusive Patent License
should be directed to: Suna Gulay French, Technology Transfer Manager,
Telephone: (240) 276-7424; Email: <a href="/cdn-cgi/l/email-protection#ccbfb9a2ade2abb9a0adb58ca2a5a4e2aba3ba"><span class="__cf_email__" data-cfemail="98ebedf6f9b6ffedf4f9e1d8f6f1f0b6fff7ee">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Intellectual Property
Group A
1. United States Provisional Patent Application No. 62/084,654
filed November 26, 2014, entitled ``Anti-Mutated KRAS T Cell
Receptors'' [HHS Reference No. E-028-2015-0-US-01];
2. PCT Patent Application No. PCT/US2015/062269 filed November 24,
2015, entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference
No. E-028-2015-1-PCT-01];
3. Australian Patent No. 2015353720 issued June 11, 2020, entitled
``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference No. E-028-2015-1-
AU-02];
4. Canadian Patent Application No. 2,968,399 effective filing date
of November 24, 2015, entitled ``Anti-Mutated KRAS T Cell Receptors''
[HHS Reference No. E-028-2015-1-CA-03];
5. Chinese Patent No. ZL201580070673.7 issued November 16, 2021,
entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference No. E-
028-2015-1-CN-04];
6. European Patent No. 3223850 issued January 8, 2020, entitled
``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference No. E-028-2015-1-
EP-05];
a. Validated in the following jurisdictions: AT, BE, CH, CZ, DE,
ES, FR, GB, GR, IE, IT, NL, NO, PL, PT, SE, SI, SK, TR;
7. Israeli Patent No. 252258 issued March 2, 2022, entitled ``Anti-
Mutated KRAS T Cell Receptors'' [HHS Reference No. E-028-2015-1-IL-06];
8. Japanese Patent No. 6863893 issued April 5, 2021, entitled
``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference No. E-028-2015-1-
JP-07];
9. Korean Patent Application No. 2017-7017289 effective filing date
of November 24, 2015, entitled ``Anti-Mutated KRAS T Cell Receptors''
[HHS Reference No. E-028-2015-1-KR-08];
10. Mexican Patent No. 384919 issued July 29, 2021, entitled
``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference No. E-028-2015-1-
MX-09];
11. New Zealand Patent Application No. 732045 effective filing date
of November 24, 2015, entitled ``Anti-Mutated KRAS T Cell Receptors''
[HHS Reference No. E-028-2015-1-NZ-10];
12. Saudi Arabian Patent No. 7697 issued March 11, 2021, entitled
``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference No. E-028-2015-1-
SA-11];
13. Singapore Patent Application No. 11201704155U effective filing
date of November 24, 2015, entitled ``Anti-Mutated KRAS T Cell
Receptors'' [HHS Reference No. E-028-2015-1-SG-12];
14. United States Patent No. 11,207,394 issued December 28, 2021,
entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference No. E-
028-2015-1-US-13];
15. Hong Kong Patent No. 1243642 issued January 22, 2021, entitled
``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference No. E-028-2015-1-
HK-14];
16. European Patent Application No. 20150279.6 filed January 3,
2020, entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference
No. E-028-2015-1-EP-15];
17. Singapore Patent Application No. 10201913978R filed December
31, 2019, entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS
Reference No. E-028-2015-1-SG-16];
18. Australian Patent Application No. 2020203465 filed May 26,
2020, entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference
No. E-028-2015-1-AU-36];
19. Saudi Arabian Patent Application No. 520420365 filed October
15, 2020, entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS
Reference No. E-028-2015-1-SA-37];
20. Hong Kong Patent Application No. 42020021375.9 effective filing
date of November 24, 2015, entitled ``Anti-Mutated KRAS T Cell
Receptors'' [HHS Reference No. E-028-2015-1-HK-38];
21. Japanese Patent Application No. 2021-063092 filed April 1,
2021, entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference
No. E-028-2015-1-JP-40];
22. Chinese Patent Application No. 202111263859.8 filed October 27,
2021, entitled ``Anti-Mutated KRAS T Cell
[[Page 80557]]
Receptors'' [HHS Reference No. E-028-2015-1-CN-41];
23. United States Patent Application No. 17/535,318 filed November
24, 2021, entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS
Reference No. E-028-2015-1-US-42];
24. Hong Kong Patent Application No. 42022054674.1 filed June 27,
2022, entitled ``Anti-Mutated KRAS T Cell Receptors'' [HHS Reference
No. E-028-2015-1-HK-43];
25. United States Provisional Patent Application No. 62/171,321
filed June 5, 2015, entitled ``Anti-Mutated KRAS T Cell Receptors''
[HHS Reference No. E-180-2015-0-US-01];
26. United States Provisional Patent Application No. 62/218,688
filed September 15, 2015, entitled ``T Cell Receptors Recognizing HLA-
CW8 Restricted Mutated KRAS'' [HHS Reference No. E-265-2015-0-US-01];
27. PCT Patent Application No. PCT/US2016/050875 filed September 9,
2016, entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted
Mutated KRAS'' [HHS Reference No. E-265-2015-0-PCT-02];
28. Australian Patent No. 2016323017 issued February 25, 2021,
entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted Mutated
KRAS'' [HHS Reference No. E-265-2015-0-AU-03];
29. Canadian Patent Application No. 2,998,869 effective filing date
of September 9, 2016, entitled ``T Cell Receptors Recognizing HLA-CW8
Restricted Mutated KRAS'' [HHS Reference No. E-265-2015-0-CA-04];
30. Chinese Patent No. ZL201680058891.3 issued October 8, 2021,
entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted Mutated
KRAS'' [HHS Reference No. E-265-2015-0-CN-05];
31. European Patent No. 3350213 issued March 31, 2021, entitled ``T
Cell Receptors Recognizing HLA-CW8 Restricted Mutated KRAS'' [HHS
Reference No. E-265-2015-0-EP-06];
a. Validated in the following jurisdictions: BE, CH, DE, DK, ES,
FR, GB, IE, IT, NL, NO and SE.
32. Israeli Patent Application No. 257840 effective filing date of
September 9, 2016, entitled ``T Cell Receptors Recognizing HLA-CW8
Restricted Mutated KRAS'' [HHS Reference No. E-265-2015-0-IL-07];
33. Japanese Patent Application No. 2018-513423 effective filing
date of September 9, 2016, entitled ``T Cell Receptors Recognizing HLA-
CW8 Restricted Mutated KRAS'' [HHS Reference No. E-265-2015-0-JP-08];
34. Korean Patent Application No. 2018-7010326, effective filing
date of September 9, 2016, entitled ``T Cell Receptors Recognizing HLA-
CW8 Restricted Mutated KRAS'' [HHS Reference No. E-265-2015-0-KR-09];
35. Mexican Patent Application No. MX/a/2018/003062 effective
filing date of September 9, 2016, entitled ``T Cell Receptors
Recognizing HLA-CW8 Restricted Mutated KRAS'' [HHS Reference No. E-265-
2015-0-MX-10];
36. New Zealand Patent Application No. 740714 effective filing date
of September 9, 2016, entitled ``T Cell Receptors Recognizing HLA-CW8
Restricted Mutated KRAS'' [HHS Reference No. E-265-2015-0-NZ-11];
37. Saudi Arabian Patent Application No. 518391109 effective filing
date of September 9, 2016, entitled ``T Cell Receptors Recognizing HLA-
CW8 Restricted Mutated KRAS'' [HHS Reference No. E-265-2015-0-SA-12];
38. Singapore Patent No. 11201802069U issued March 31, 2022,
entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted Mutated
KRAS'' [HHS Reference No. E-265-2015-0-SG-13];
39. United States Patent No. 10,556,940 issued February 11, 2020,
entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted Mutated
KRAS'' [HHS Reference No. E-265-2015-0-US-14];
40. Hong Kong Patent No. HK1257902 issued December 24, 2021,
entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted Mutated
KRAS'' [HHS Reference No. E-265-2015-0-HK-15];
41. United States Patent Application No. 16/739,310 filed January
10, 2020, entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted
Mutated KRAS'' [HHS Reference No. E-265-2015-0-US-16];
42. Singapore Patent Application No. 10201913868X filed December
30, 2019, entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted
Mutated KRAS'' [HHS Reference No. E-265-2015-0-SG-17];
43. Australian Patent No. 2021200833 issued August 18, 2022,
entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted Mutated
KRAS'' [HHS Reference No. E-265-2015-0-AU-18];
44. European Patent Application No. 21162567.8 filed March 15,
2021, entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted
Mutated KRAS'' [HHS Reference No. E-265-2015-0-EP-19];
45. Saudi Arabian Patent Application No. 521421309 filed February
23, 2021, entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted
Mutated KRAS'' [HHS Reference No. E-265-2015-0-SA-20];
46. Chinese Patent Application No. 202111083392.9 filed September
15, 2021, entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted
Mutated KRAS'' [HHS Reference No. E-265-2015-0-CN-33];
47. New Zealand Patent Application No. 779633 filed September 2,
2021, entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted
Mutated KRAS'' [HHS Reference No. E-265-2015-0-NZ-34];
48. Australian Patent Application No. 2022209229 filed July 26,
2022, entitled ``T Cell Receptors Recognizing HLA-CW8 Restricted
Mutated KRAS'' [HHS Reference No. E-265-2015-0-AU-35];
49. United States Provisional Patent Application No. 62/369,883
filed August 2, 2016, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS
Reference No. E-175-2016-0-US-01];
50. PCT Patent Application No. PCT/US2017/044615 filed July 31,
2017, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No.
E-175-2016-0-PCT-02];
51. Australian Patent Application No. 2017306038 effective filing
date of July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors''
[HHS Reference No. E-175-2016-0-AU-03];
52. Canadian Patent Application No. 3,032,870 effective filing date
of July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS
Reference No. E-175-2016-0-CA-04];
53. Chinese Patent Application No. 201780059356.4 effective filing
date of July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors''
[HHS Reference No. E-175-2016-0-CN-05];
54. European Patent No. 3494133 issued July 6, 2022, entitled
``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-2016-0-EP-
06];
a. Validated in the following jurisdictions: AL, AT, BE, BG, CH,
CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, HR, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM and TR.
55. Japanese Patent Application No. 2019-505220 effective filing
date of July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors''
[HHS Reference No. E-175-2016-0-JP-07];
56. United States Patent No. 10,611,816 issued April 7, 2020,
entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-
2016-0-US-08];
57. Israeli Patent Application No. 264425 effective filing date of
July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS
Reference No. E-175-2016-0-IL-09];
58. Korean Patent Application No. 2019-7005837 effective filing
date of July 31, 2017, entitled ``Anti-KRAS
[[Page 80558]]
G12D T Cell Receptors'' [HHS Reference No. E-175-2016-0-KR-10];
59. Singapore Patent Application No. 11201900654Q effective filing
date of July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors''
[HHS Reference No. E-175-2016-0-SG-11];
60. Hong Kong Patent Application No. 19133082.8 effective filing
date of July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors''
[HHS Reference No. E-175-2016-0-HK-12];
61. Hong Kong Patent Application No. 19132196.7 effective filing
date of July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors''
[HHS Reference No. E-175-2016-0-HK-13];
62. Singapore Patent Application No. 10201913959W filed December
31, 2019, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference
No. E-175-2016-0-SG-14];
63. United States Patent No. 11,208,456 issued December 28, 2021,
entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-
2016-0-US-15];
64. United States Patent Application No. 17/345,390 filed June 11,
2021, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No.
E-175-2016-0-US-16];
65. United States Patent Application No. 17/541,619 filed December
3, 2021, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference
No. E-175-2016-0-US-17];
66. Japanese Patent Application No. 2021-199878 filed December 9,
2021, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No.
E-175-2016-0-JP-18];
67. European Patent Application No. 22182473.3 filed July 1, 2022,
entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-
2016-0-EP-19];
68. United States Provisional Patent Application No. 62/560,930
filed September 20, 2017, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-US-01];
69. PCT Patent Application No. PCT/US2018/051641 filed September
19, 2018, entitled ``HLA Class II-Restricted T Cell Receptors Against
Mutated RAS'' [HHS Reference No. E-181-2017-0-PCT-02];
70. Argentina Patent Application No. P180102695 effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-AR-03];
71. Taiwanese Patent Application No. 107133221 filed September 20,
2018, entitled ``HLA Class II-Restricted T Cell Receptors Against
Mutated RAS'' [HHS Reference No. E-181-2017-0-TW-05];
72. United States Patent No. 11,306,132 issued April 19, 2022,
entitled ``HLA Class II-Restricted T Cell Receptors Against Mutated
RAS'' [HHS Reference No. E-181-2017-0-US-06];
73. Australian Patent Application No. 2018335274 effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-AU-07];
74. Brazilian Patent Application No. BR112020005469-0 effective
filing date of September 19, 2018, entitled ``HLA Class II-Restricted T
Cell Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-
BR-08];
75. Canadian Patent Application No. 3,076,339 effective filing date
of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-CA-09];
76. Chinese Patent Application No. 201880060535.4 effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-CN-10];
77. Costa Rican Patent Application No. 2020-0150 effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-CR-11];
78. Eurasian Patent Application No. 202090652 effective filing date
of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-EA-12];
79. European Patent Application No. 18792591.2 effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-EP-13];
80. Israeli Patent Application No. 273254 effective filing date of
September 19, 2018, entitled ``HLA Class II-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-181-2017-0-IL-14];
81. Indian Patent Application No. 202047011647 effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-IN-15];
82. Japanese Patent Application No. 2020-516422 effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-JP-16];
83. Korean Patent Application No. 2020-7011112 effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-KR-17];
84. Mexican Patent Application No. MX/a/2020/003117 effective
filing date of September 19, 2018, entitled ``HLA Class II-Restricted T
Cell Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-
MX-18];
85. New Zealand Patent Application No. 762831 effective filing date
of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-NZ-19];
86. Singapore Patent Application No. 11202002425P effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-SG-20];
87. Hong Kong Patent Application No. 62020019700.7 effective filing
date of September 19, 2018, entitled ``HLA Class II-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-181-2017-0-HK-21];
88. Brazilian Patent Application No. BR122021018418-6 filed
September 16, 2021, entitled ``HLA Class II-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-181-2017-0-BR-22];
89. United States Patent Application No. 17/692,787 filed March 11,
2022, entitled ``HLA Class II-Restricted T Cell Receptors Against
Mutated RAS'' [HHS Reference No. E-181-2017-0-US-23];
90. United States Provisional Patent Application No. 62/594,244
filed December 4, 2017, entitled ``HLA Class I-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-239-2017-0-US-01];
91. PCT Patent Application No. PCT/US2018/063581 filed December 3,
2018, entitled ``HLA Class I-Restricted T Cell Receptors Against
Mutated RAS'' [HHS Reference No. E-239-2017-0-PCT-02];
92. Australian Patent Application No. 2018378200 effective filing
date of December 3, 2018, entitled ``HLA Class I-Restricted T Cell
Receptors Against Mutated RAS'' [HHS Reference No. E-239-2017-0-AU-03];
93. Brazilian Patent Application No. BR112020011111-2 effective
filing date of December 3, 2018, entitled ``HLA Class I-Restricted T
Cell Receptors Against Mutated RAS'' [HHS Reference No. E-239-2017-0-
BR-04];
94. Canadian Application No. 3,084,246 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-CA-05];
[[Page 80559]]
95. Chinese Application No. 201880087270.7 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-CN-06];
96. Costa Rican Application No. 2020-0287 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-CR-07];
97. Eurasian Application No. 202091335 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-EA-08];
98. European Application No. 18830062.8 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-EP-09];
99. Israeli Application No. 275031 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-IL-10];
100. Indian Application No. 202047026991 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-IN-11];
101. Japanese Application No. 2020-530325 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-JP-12];
102. Korean Application No. 2020-7019185 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-KR-13];
103. Mexican Application No. MX/a/2020/005765 effective filing date
of December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-MX-14];
104. New Zealand Application No. 765440 effective filing date of
December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-NZ-15];
105. Singapore Application No. 11202005236Q effective filing date
of December 3, 2018, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-SG-16];
106. United States Patent Application No. 16/769,144 effective
filing date of December 3, 2018, entitled ``HLA Class I-Restricted T
Cell Receptors Against Mutated RAS'' [HHS Reference No. E-239-2017-0-
US-17];
107. Hong Kong Patent Application No. 62021026617.2 effective
filing date of December 3, 2018, entitled ``HLA Class I-Restricted T
Cell Receptors Against Mutated RAS'' [HHS Reference No. E-239-2017-0-
HK-18];
108. Brazilian Patent Application No. BR122021024382-4 filed
December 2, 2021, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-BR-19];
109. United States Patent Application No. 17/931,391 filed
September 12, 2022, entitled ``HLA Class I-Restricted T Cell Receptors
Against Mutated RAS'' [HHS Reference No. E-239-2017-0-US-20];
110. United States Provisional Patent Application No. 62/795,203
filed January 22, 2019, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-029-
2019-0-US-01];
111. Taiwanese Patent Application No. 109102511 filed January 22,
2020, entitled ``HLA Class II-Restricted T Cell Receptors Against RAS
with G12R Mutation'' [HHS Reference No. E-029-2019-0-TW-02];
112. PCT Patent Application No. PCT/US2020/014382 filed January 21,
2020, entitled ``HLA Class II-Restricted T Cell Receptors Against RAS
with G12R Mutation'' [HHS Reference No. E-029-2019-0-PCT-03];
113. Australian Patent Application No. 2020211922 effective filing
date of January 21, 2020, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-029-
2019-0-AU-04];
114. Canadian Patent Application No. 3,127,096 effective filing
date of January 21, 2020, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-029-
2019-0-CA-05];
115. Chinese Patent Application No. 202080010373.0 effective filing
date of January 21, 2020, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-029-
2019-0-CN-06];
116. European Patent Application No. 20705599.7 effective filing
date of January 21, 2020, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-029-
2019-0-EP-07];
117. Japanese Patent Application No. 2021-542206 effective filing
date of January 21, 2020, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-029-
2019-0-JP-08];
118. Korean Patent Application No. 2021-7026169 effective filing
date of January 21, 2020, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-029-
2019-0-KR-09];
119. United States Patent Application No. 17/424,591 effective
filing date of January 21, 2020, entitled ``HLA Class II-Restricted T
Cell Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-
029-2019-0-US-10];
120. Hong Kong Patent Application No. 62022048432.8 effective
filing date of January 21, 2020, entitled ``HLA Class II-Restricted T
Cell Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-
029-2019-0-HK-11];
121. Hong Kong Patent Application No. 62022047561.5 effective
filing date of January 21, 2020, entitled ``HLA Class II-Restricted T
Cell Receptors Against RAS with G12R Mutation'' [HHS Reference No. E-
029-2019-0-HK-12];
122. United States Provisional Patent Application No. 62/975,544
filed February 12, 2020, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
US-01];
123. PCT Patent Application No. PCT/US2021/017794 filed February
12, 2021, entitled ``HLA Class I-Restricted T Cell Receptors Against
RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-PCT-02];
124. Taiwanese Patent Application No. 110105194 filed February 12,
2021, entitled ``HLA Class I-Restricted T Cell Receptors Against RAS
with G12D Mutation'' [HHS Ref. No. E-031-2020-0-TW-03];
125. Australian Patent Application No. 2021221138 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
AU-04];
126. Canadian Patent Application No. 3,168,015 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
CA-05];
127. Chinese Patent Application No. 202180014038.2 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
CN-06];
128. European Patent Application No. 21710730.9 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
EP-07];
129. Indian Patent Application No. 202247050250 effective filing
date of February 12, 2021, entitled ``HLA Class
[[Page 80560]]
I-Restricted T Cell Receptors Against RAS with G12D Mutation'' [HHS
Ref. No. E-031-2020-0-IN-08];
130. Japanese Patent Application No. 2022-548811 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
JP-09];
131. Korean Patent Application No. 2022-7031175 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
KR-10];
132. Singapore Patent Application No. 11202251837Y effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
SG-11];
133. United Kingdom Patent Application No. 2211733.7 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-
2020-0-GB-12];
134. United States Patent Application No. 17/799,163 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-
2020-0-US-13];
135. Brazilian Patent Application No. BR112022015888-2 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-
2020-0-BR-14];
136. Chilean Patent Application No. 02208-2022 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
CL-15];
137. Colombian Patent Application No. NC2022/0012922 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-
2020-0-CO-16];
138. Israeli Patent Application No. 295252 effective filing date of
February 12, 2021, entitled ``HLA Class I-Restricted T Cell Receptors
Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-IL-18];
139. Mexican Patent Application No. MX/a/2022/009654 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-
2020-0-MX-19];
140. New Zealand Patent Application No. 790950 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
NZ-20];
141. South African Patent Application No. 2022/08853 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-
2020-0-ZA-21];
142. Cuban Patent Application No. 2022-0044 effective filing date
of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
CU-22];
143. Russian Patent Application No. 2022124004 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-031-2020-0-
RU-23];
144. United States Provisional Patent Application No. 62/976,655
filed February 14, 2020, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-0-
US-01];
145. United States Provisional Patent Application No. 63/060,340
filed August 3, 2020, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-190-2020-0-
US-01];
146. PCT Patent Application No. PCT/US2021/017852 filed February
12, 2021, entitled ``HLA Class I-Restricted T Cell Receptors Against
RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-PCT-01];
147. Taiwanese Patent Application No. 110105193 filed February 12,
2021, entitled ``HLA Class I-Restricted T Cell Receptors Against RAS
with G12V Mutation'' [HHS Ref. No. E-074-2020-1-TW-02];
148. Australian Patent Application No. 2021220957 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-
AU-03];
149. Canadian Patent Application No. 3,167,382 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-
CA-04];
150. Chinese Patent Application No. 202180014281.4 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-
CN-05];
151. European Patent Application No. 21710740.8 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-
EP-06];
152. Indian Patent Application No. 202247050807 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-
IN-07];
153. Japanese Patent Application No. 2022-549088 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-
JP-08];
154. Korean Patent Application No. 2022-7031589 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-
KR-09];
155. Singapore Patent Application No. 11202251947C effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-
SG-10];
156. United Kingdom Patent Application No. 2211757.6 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-
2020-1-GB-11];
157. United States Patent Application No. 17/799,193 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-
2020-1-US-12];
158. Brazilian Patent Application No. BR112022015897-1 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-
2020-1-BR-13];
159. Mexican Patent Application No. MX/a/2022/009825 effective
filing date of February 12, 2021, entitled ``HLA Class I-Restricted T
Cell Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-
2020-1-MX-14];
160. New Zealand Patent Application No. 791024 effective filing
date of February 12, 2021, entitled ``HLA Class I-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-074-2020-1-
NZ-15];
161. United States Provisional Patent Application No. 62/981,856
filed February 26, 2020, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-
US-01];
162. PCT Patent Application No. PCT/US2021/019775 filed February
26, 2021, entitled ``HLA Class II-Restricted T Cell Receptors Against
RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-PCT-02];
163. Taiwanese Patent Application No. 110106886 filed February 26,
2021,
[[Page 80561]]
entitled ``HLA Class II-Restricted T Cell Receptors Against RAS with
G12V Mutation'' [HHS Ref. No. E-088-2020-0-TW-03];
164. Australian Patent Application No. 2021225872 effective filing
date of February 26, 2021, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-
AU-04];
165. Canadian Patent Application No. 3,169,086 effective filing
date of February 26, 2021, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-
CA-05];
166. Chinese Patent Application No. 202180016761.4 effective filing
date of February 26, 2021, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-
CN-06];
167. European Patent Application No. 21712694.5 effective filing
date of February 26, 2021, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-
EP-07];
168. Indian Patent Application No. 202247052620 effective filing
date of February 26, 2021, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-
IN-08];
169. Korean Patent Application No. 2022-7033222 effective filing
date of February 26, 2021, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-
KR-10];
170. Singapore Patent Application No. 1120225235K effective filing
date of February 26, 2021, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-
SG-11];
171. United Kingdom Patent Application No. 2212195.8 effective
filing date of February 26, 2021, entitled ``HLA Class II-Restricted T
Cell Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-
2020-0-GB-12];
172. United States Patent Application No. 17/802,464 effective
filing date of February 26, 2021, entitled ``HLA Class II-Restricted T
Cell Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-
2020-0-US-13];
173. Brazilian Patent Application No. BR112022016661-3 effective
filing date of February 26, 2021, entitled ``HLA Class II-Restricted T
Cell Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-
2020-0-BR-14];
174. Mexico Patent Application No. MX/a/2022/010157 effective
filing date of February 26, 2021, entitled ``HLA Class II-Restricted T
Cell Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-
2020-0-MX-15];
175. New Zealand Patent Application No. 791348 effective filing
date of February 26, 2021, entitled ``HLA Class II-Restricted T Cell
Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-088-2020-0-
NZ-16];
176. United States Provisional Patent Application No. 63/050,931
filed July 13, 2020, entitled ``HLA Class II-Restricted DRB T Cell
Receptors Against RAS with G12D Mutation'' [HHS Ref. No. E-165-2020-0-
US-01];
177. PCT Patent Application No. PCT/US2021/041375 filed July 13,
2021, entitled ``HLA Class II-Restricted DRB T Cell Receptors Against
RAS with G12D Mutation'' [HHS Ref. No. E-165-2020-0-PCT-02];
178. United States Provisional Patent Application No. 63/052,502
filed July 16, 2020, entitled ``HLA Class II-Restricted DRB1*01:01 T
Cell Receptors Against RAS with G12V Mutation'' [HHS Ref. No. E-172-
2020-0-US-01];
179. PCT Patent Application No. PCT/US2021/041737 filed July 15,
2021, entitled ``HLA Class II-Restricted DRB1*01:01 T Cell Receptors
Against RAS with G12V Mutation'' [HHS Ref. No. E-172-2020-0-PCT-02];
180. United States Provisional Patent Application No. 63/086,674
filed October 2, 2020, entitled ``HLA Class II-Restricted DQ T Cell
Receptors Against RAS with G13D Mutation'' [HHS Ref. No. E-189-2020-0-
US-01];
181. PCT Patent Application No. PCT/US2021/053060 filed October 1,
2021, entitled ``HLA Class II-Restricted DQ T Cell Receptors Against
RAS with G13D Mutation'' [HHS Ref. No. E-189-2020-1-PCT-01];
182. Taiwanese Patent Application No. 110136658 filed October 1,
2021, entitled ``HLA Class II-Restricted DQ T Cell Receptors Against
RAS with G13D Mutation'' [HHS Ref. No. E-189-2020-1-TW-02]; and
183. United States Provisional Patent Application No. 63/284,884
filed December 1, 2021, entitled ``HLA-A3-Restricted T Cell Receptors
Against RAS with G12V Mutation'' [HHS Ref. No. E-219-2021-0-US-01].
Group B
1. United States Provisional Patent Application No. 62/565,383
filed September 29, 2017, entitled ``T Cell Receptors Recognizing
Mutated P53'' [HHS Reference No. E-237-2017-0-US-01];
2. PCT Patent Application No. PCT/US2018/051285 filed September 17,
2018, entitled ``T Cell Receptors Recognizing Mutated P53'' [HHS
Reference No. E-237-2017-2-PCT-01];
3. Australian Patent Application No. 2018342246 effective filing
date of September 17, 2018, entitled ``T Cell Receptors Recognizing
Mutated P53'' [HHS Reference No. E-237-2017-2-AU-02];
4. Brazilian Patent Application No. BR112020006012-7 effective
filing date of September 17, 2018, entitled ``T Cell Receptors
Recognizing Mutated P53'' [HHS Reference No. E-237-2017-2-BR-03];
5. Canadian Patent Application No. 3,077,024 effective filing date
of September 17, 2018, entitled ``T Cell Receptors Recognizing Mutated
P53'' [HHS Reference No. E-237-2017-2-CA-04];
6. Chinese Patent Application No. 201880074539.8 effective filing
date of September 17, 2018, entitled ``T Cell Receptors Recognizing
Mutated P53'' [HHS Reference No. E-237-2017-2-CN-05];
7. Costa Rican Application No. 2020-0170 effective filing date of
September 17, 2018, entitled ``T Cell Receptors Recognizing Mutated
P53'' [HHS Reference No. E-237-2017-2-CR-06];
8. Eurasian Application No. 202090757 effective filing date of
September 17, 2018, entitled ``T Cell Receptors Recognizing Mutated
P53'' [HHS Reference No. E-237-2017-2-EA-07];
9. European Patent Application No. 18780006.5 effective filing date
of September 17, 2018, entitled ``T Cell Receptors Recognizing Mutated
P53'' [HHS Reference No. E-237-2017-2-EP-08];
10. Israeli Patent Application No. 273515 effective filing date of
September 17, 2018, entitled ``T Cell Receptors Recognizing Mutated
P53'' [HHS Reference No. E-237-2017-2-IL-09];
11. Indian Patent Application No. 202047013911 effective filing
date of September 17, 2018, entitled ``T Cell Receptors Recognizing
Mutated P53'' [HHS Reference No. E-237-2017-2-IN-10];
12. Japanese Patent Application No. 2020-517556 effective filing
date of September 17, 2018, entitled ``T Cell Receptors Recognizing
Mutated P53'' [HHS Reference No. E-237-2017-2-JP-11];
13. Korean Patent Application No. 2020-7012344 effective filing
date of September 17, 2018, entitled ``T Cell Receptors Recognizing
Mutated P53'' [HHS Reference No. E-237-2017-2-KR-12];
14. Mexican Application No. MX/a/2020/003504 effective filing date
of September 17, 2018, entitled ``T Cell Receptors Recognizing Mutated
P53''
[[Page 80562]]
[HHS Reference No. E-237-2017-2-MX-13];
15. New Zealand Patent Application No. 763023 effective filing date
of September 17, 2018, entitled ``T Cell Receptors Recognizing Mutated
P53'' [HHS Reference No. E-237-2017-2-NZ-14];
16. Singapore Patent Application No. 11202002636P effective filing
date of September 17, 2018, entitled ``T Cell Receptors Recognizing
Mutated P53'' [HHS Reference No. E-237-2017-2-SG-15];
17. United States Patent Application No. 16/651,242 effective
filing date of September 17, 2018, entitled ``T Cell Receptors
Recognizing Mutated P53'' [HHS Reference No. E-237-2017-2-US-16];
18. Hong Kong Patent Application No. 62020021272.3 filed November
30, 2020, entitled ``T Cell Receptors Recognizing Mutated P53'' [HHS
Reference No. E-237-2017-2-HK-17];
19. Brazilian Patent Application No. BR122021018454-2 filed
September 16, 2021, entitled ``T Cell Receptors Recognizing Mutated
P53'' [HHS Reference No. E-237-2017-2-BR-18];
20. United States Provisional Patent Application No. 62/867,619
filed June 27, 2019, entitled ``T Cell Receptors Recognizing R175H or
Y220C Mutation in P53'' [HHS Reference No. E-135-2019-0-US-01];
21. PCT Patent Application No. PCT/US2020/039785, filed June 26,
2020, entitled ``T Cell Receptors Recognizing R175H or Y220C Mutation
in P53'' [HHS Reference No. E-135-2019-0-PCT-02];
22. Taiwanese Patent Application No. 109121744 filed June 26, 2020,
entitled ``T Cell Receptors Recognizing R175H or Y220C Mutation in
P53'' [HHS Reference No. E-135-2019-0-TW-03];
23. Australian Patent Application No. 2020308004 filed January 6,
2022, entitled ``T Cell Receptors Recognizing R175H or Y220C Mutation
in P53'' [HHS Reference No. E-135-2019-0-AU-04];
24. Brazilian Patent Application No. BR112021026408-6 filed
December 24, 2021, entitled ``T Cell Receptors Recognizing R175H or
Y220C Mutation in P53'' [HHS Reference No. E-135-2019-0-BR-05];
25. Canadian Patent Application No. 3,144,070 filed December 16,
2021, entitled ``T Cell Receptors Recognizing R175H or Y220C Mutation
in P53'' [HHS Reference No. E-135-2019-0-CA-06];
26. Chinese Patent Application No. 202080047882.0 filed December
27, 2021, entitled ``T Cell Receptors Recognizing R175H or Y220C
Mutation in P53'' [HHS Reference No. E-135-2019-0-CN-07];
27. European Patent Application No. 20742583.6 filed January 27,
2022, entitled ``T Cell Receptors Recognizing R175H or Y220C Mutation
in P53'' [HHS Reference No. E-135-2019-0-EP-08];
28. Indian Patent Application No. 202247003029 filed January 19,
2022, entitled ``T Cell Receptors Recognizing R175H or Y220C Mutation
in P53'' [HHS Reference No. E-135-2019-0-IN-09];
29. Japanese Patent Application No. 2021-576970 filed December 24,
2021, entitled ``T Cell Receptors Recognizing R175H or Y220C Mutation
in P53'' [HHS Reference No. E-135-2019-0-JP-10];
30. Mexican Patent Application No. MX/a/2021/015877 filed December
16, 2021, entitled ``T Cell Receptors Recognizing R175H or Y220C
Mutation in P53'' [HHS Reference No. E-135-2019-0-MX-11];
31. Russian Patent Application No. 2022101295 filed January 20,
2022, entitled ``T Cell Receptors Recognizing R175H or Y220C Mutation
in P53'' [HHS Reference No. E-135-2019-0-RU-12];
32. Singapore Patent Application No. 11202113949V filed December
15, 2021, entitled ``T Cell Receptors Recognizing R175H or Y220C
Mutation in P53'' [HHS Reference No. E-135-2019-0-SG-13];
33. South African Patent Application No. 2022/00598 filed January
12, 2022, entitled ``T Cell Receptors Recognizing R175H or Y220C
Mutation in P53'' [HHS Reference No. E-135-2019-0-ZA-14];
34. Korean Patent Application No. 2022-7002872 filed January 26,
2022, entitled ``T Cell Receptors Recognizing R175H or Y220C Mutation
in P53'' [HHS Reference No. E-135-2019-0-KR-15];
35. United States Patent Application No. 17/620,942 filed December
20, 2021, entitled ``T Cell Receptors Recognizing R175H or Y220C
Mutation in P53'' [HHS Reference No. E-135-2019-0-US-16];
36. United States Provisional Patent Application No. 63/074,747
filed September 4, 2020, entitled ``T Cell Receptors Recognizing R273C
or Y220C Mutation in P53'' [HHS Reference No. E-173-2020-0-US-01];
37. PCT Patent Application No. PCT/US2021/048786 filed September 2,
2021, entitled ``T Cell Receptors Recognizing R273C or Y220C Mutation
in P53'' [HHS Reference No. E-173-2020-0-PCT-02];
38. Taiwanese Patent Application No. 110132552 filed September 2,
2021, entitled ``T Cell Receptors Recognizing R273C or Y220C Mutation
in P53'' [HHS Reference No. E-173-2020-0-TW-03];
39. United States Provisional Patent Application No. 63/185,805
filed May 7, 2021, entitled ``T Cell Receptors Recognizing C135Y, R175H
or M237I Mutation in P53'' [HHS Reference No. E-101-2021-0-US-01]; and
40. PCT Patent Application No. PCT/US2022/028066 filed May 6, 2022,
entitled ``T Cell Receptors Recognizing C135Y, R175H or M237I Mutation
in P53'' [HHS Reference No. E-101-2021-0-PCT-02].
Group C
1. United States Provisional Patent Application No. 62/004,335
filed May 29, 2014, entitled ``Anti-Human Papillomavirus 16 E7 T Cell
Receptors'' [HHS Reference No. E-176-2014-0-US-01];
2. PCT Patent Application No. PCT/US2015/033129 filed May 29, 2015,
entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS
Reference No. E-176-2014-0-PCT-02];
3. Australian Patent No. 2015266818 issued January 16, 2020,
entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS
Reference No. E-176-2014-0-AU-03];
4. Brazilian Patent Application No. BR112016027805-4 effective
filing date of May 29, 2015, entitled ``Anti-Human Papillomavirus 16 E7
T Cell Receptors'' [HHS Reference No. E-176-2014-0-BR-04];
5. Canadian Patent Application No. 2,950,192 effective filing date
of May 29, 2015, entitled ``Anti-Human Papillomavirus 16 E7 T Cell
Receptors'' [HHS Reference No. E-176-2014-0-CA-05];
6. Chinese Patent No. ZL201580031789.X issued May 4, 2021, entitled
``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No.
E-176-2014-0-CN-06];
7. European Patent No. 3149031 issued December 18, 2019, entitled
``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No.
E-176-2014-0-EP-07];
a. Validated in the following jurisdictions: AL, AT, BE, BG, CH,
CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM and TR.
8. Israeli Patent No. 248797 issued September 1, 2021, entitled
``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No.
E-176-2014-0-IL-08];
9. Japanese Patent No. 6742991 issued August 19, 2020, entitled
``Anti-Human
[[Page 80563]]
Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No. E-176-2014-
0-JP-09];
10. Korean Patent Application No. 2016-7033189 effective filing
date of May 29, 2015, entitled ``Anti-Human Papillomavirus 16 E7 T Cell
Receptors'' [HHS Reference No. E-176-2014-0-KR-10];
11. Mexican Patent No. 375379 issued September 25, 2020, entitled
``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No.
E-176-2014-0-MX-11];
12. Saudi Arabian Patent No. 7456 issued January 5, 2021, entitled
``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No.
E-176-2014-0-SA-12];
13. United States Patent No. 10,174,098 issued January 8, 2019,
entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS
Reference No. E-176-2014-0-US-13];
14. Hong Kong Patent No. HK1236203 issued January 8, 2021, entitled
``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No.
E-176-2014-0-HK-14];
15. United States Patent No. 10,870,687 issued December 22, 2020,
entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS
Reference No. E-176-2014-0-US-15];
16. European Patent Application No. 19217074.4 filed December 17,
2019, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-EP-16];
17. Australian Patent No. 2019283892 issued May 13, 2021, entitled
``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No.
E-176-2014-0-AU-17];
18. Japanese Patent No. 6997267 issued December 20, 2021, entitled
``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No.
E-176-2014-0-JP-53];
19. Saudi Arabian Patent Application No. 520412601 filed August 10,
2020, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-SA-54];
20. Hong Kong Patent Application No. 42020020661.3 filed November
24, 2020, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-HK-55];
21. Mexican Patent Application No. MX/a/2020/010035 filed September
24, 2020, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-MX-56];
22. United States Patent No. 11,434,272 issued September 6, 2020,
entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS
Reference No. E-176-2014-0-US-57];
23. Australian Patent Application No. 2021202227 filed April 13,
2021, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-AU-58];
24. Chinese Patent Application No. 20210399056.9 filed April 14,
2021, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-CN-59];
25. Israeli Patent No. 282518 issued July 2, 2022, entitled ``Anti-
Human Papillomavirus 16 E7 T Cell Receptors'' [HHS Reference No. E-176-
2014-0-IL-60];
26. Hong Kong Patent Application No. 42022046605.6 filed January
19, 2022, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-HK-62];
27. Japanese Patent Application No. 2021-203953 filed December 16,
2021, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-JP-63];
28. Israeli Patent Application No. 290655 filed February 16, 2022,
entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors'' [HHS
Reference No. E-176-2014-0-IL-64];
29. United States Patent Application No. 17/816,496 filed August 1,
2022, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-US-65]; and
30. Korean Patent Application No. 2022-7032043 filed September 15,
2022, entitled ``Anti-Human Papillomavirus 16 E7 T Cell Receptors''
[HHS Reference No. E-176-2014-0-KR-66].
Group D
1. United States Provisional Patent Application No. 61/535,086
filed September 15, 2011, entitled ``T Cell Receptors Recognizing HLA-
A1- or HLA-CW7-Restricted MAGE'' [HHS Reference No. E-266-2011-0-US-
01];
2. PCT Patent Application No. PCT/US2012/051623 filed September 11,
2012, entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-
Restricted MAGE'' [HHS Reference No. E-266-2011-0-PCT-02];
3. Australian Patent No. 2012309830 issued July 13, 2017, entitled
``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE''
[HHS Reference No. E-266-2011-0-AU-03];
4. Canadian Patent No. 2,848,209 issued June 1, 2021, entitled ``T
Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE'' [HHS
Reference No. E-266-2011-0-CA-04];
5. European Patent No. 2755997 issued July 4, 2018, entitled ``T
Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE'' [HHS
Reference No. E-266-2011-0-EP-05];
a. Validated in the following jurisdictions: AT, BE, CH, CZ, DE,
ES, FR, GB, GR, IE, IT, NL, NO, PL, PT, SE, SI, SK and TR.
6. Japanese Patent No. 6415322 issued October 12, 2018, entitled
``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE''
[HHS Reference No. E-266-2011-0-JP-06];
7. United States Patent Application No. 14/344,354 filed March 14,
2014, entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-
Restricted MAGE'' [HHS Reference No. E-266-2011-0-US-07];
8. Chinese Patent Application No. 201280055972.X filed May 14,
2014, entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-
Restricted MAGE'' [HHS Reference No. E-266-2011-0-CN-08];
9. Israeli Patent No. 231323 issued November 30, 2019, entitled ``T
Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE'' [HHS
Reference No. E-266-2011-0-IL-09];
10. Australian Patent No. 2017204103 issued June 20, 2019, entitled
``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE''
[HHS Reference No. E-266-2011-0-AU-10];
11. European Patent No. 3392270 issued August 26, 2020, entitled
``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE''
[HHS Reference No. E-266-2011-0-EP-11];
a. Validated in: AT, BE, CH, CZ, DE, ES, FR, GB, GR, IE, IT, NL,
NO, PL, PT, SE, SI, SK and TR.
12. Chinese Patent Application No. 201811170958.X filed October 8,
2018, entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-
Restricted MAGE'' [HHS Reference No. E-266-2011-0-CN-14];
13. United States Patent No. 11,306,131 issued April 19, 2022,
entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted
MAGE'' [HHS Reference No. E-266-2011-0-US-32];
14. Japanese Patent No. 6855426 issued March 19, 2021, entitled ``T
Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE'' [HHS
Reference No. E-266-2011-0-JP-33];
15. Hong Kong Patent No. HK1262936 issued June 4, 2021, entitled
``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE''
[HHS Reference No. E-266-2011-0-HK-34];
16. Hong Kong Patent Application No. 19129278.8 filed September 6,
2019, entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-
Restricted MAGE'' [HHS Reference No. E-266-2011-0-HK-35];
[[Page 80564]]
17. Israeli Patent No. 268157 issued July 30, 2021, entitled ``T
Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE'' [HHS
Reference No. E-266-2011-0-IL-36];
18. European Patent Application No. 20192082.4 filed July 18, 2019,
entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted
MAGE'' [HHS Reference No. E-266-2011-0-EP-37];
19. Israeli Patent No. 268157 issued June 2, 2022, entitled ``T
Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted MAGE'' [HHS
Reference No. E-266-2011-0-IL-57];
20. Japanese Patent Application No. 2021-043845 filed March 17,
2021, entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-
Restricted MAGE'' [HHS Reference No. E-266-2011-0-JP-58];
21. Canadian Patent Application No. 3,114,877 filed April 13, 2021,
entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted
MAGE'' [HHS Reference No. E-266-2011-0-CA-59];
22. Israeli Patent Application No. 290105 filed January 25, 2022,
entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-Restricted
MAGE'' [HHS Reference No. E-266-2011-0-IL-60];
23. United States Patent Application No. 17/691,569 filed March 10,
2022, entitled ``T Cell Receptors Recognizing HLA-A1- or HLA-CW7-
Restricted MAGE'' [HHS Reference No. E-266-2011-0-US-61];
24. United States Provisional Patent Application No. 61/701,056
filed September 14, 2012, entitled ``T Cell Receptors Recognizing MHC
Class II-Restricted Mage-A3'' [HHS Reference No. E-230-2012-0-US-01];
25. PCT Patent Application No. PCT/US2013/059608 filed September
13, 2013, entitled ``T Cell Receptors Recognizing MHC Class II-
Restricted Mage-A3'' [HHS Reference No. E-230-2012-0-PCT-02];
26. Australian Patent No. 2013315391 issued September 21, 2017,
entitled ``T Cell Receptors Recognizing MHC Class II-Restricted Mage-
A3'' [HHS Reference No. E-230-2012-0-AU-03];
27. Canadian Patent Application No. 2,884,743 filed September 13,
2013, entitled ``T Cell Receptors Recognizing MHC Class II-Restricted
Mage-A3'' [HHS Reference No. E-230-2012-0-CA-04];
28. Chinese Patent No. ZL201380059102.4 issued September 24, 2021,
entitled ``T Cell Receptors Recognizing MHC Class II-Restricted Mage-
A3'' [HHS Reference No. E-230-2012-0-CN-05];
29. European Patent No. 2895509 issued December 4, 2019, entitled
``T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-EP-06];
a. Validated in the following jurisdictions: AL, AT, BE, BG, CH,
CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU,
LV, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM and TR.
30. Israeli Patent No. 237560 issued September 1, 2020, entitled
``T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-IL-07];
31. Japanese Patent No. 6461796 issued January 11, 2019, entitled
``T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-JP-08];
32. Korean Patent No. 2165350 issued October 6, 2020, entitled ``T
Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-KR-09];
33. Mexican Patent No. 367279 issued August 13, 2019, entitled ``T
Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-MX-10];
34. United States Patent No. 9,879,065 issued January 30, 2018,
entitled ``T Cell Receptors Recognizing MHC Class II-Restricted Mage-
A3'' [HHS Reference No. E-230-2012-0-US-11];
35. Australian Patent No. 2017219019 issued August 22, 2019,
entitled ``T Cell Receptors Recognizing MHC Class II-Restricted Mage-
A3'' [HHS Reference No. E-230-2012-0-AU-12];
36. United States Patent No. 10,611,815 issued April 7, 2020,
entitled ``T Cell Receptors Recognizing MHC Class II-Restricted Mage-
A3'' [HHS Reference No. E-230-2012-0-US-13];
37. Japanese Patent No. 6728326 issued July 3, 2020, entitled ``T
Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-JP-14];
38. Australian Patent No. 2019213329 issued June 24, 2021, entitled
``T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-AU-15];
39. Mexican Patent Application No. MX/a/2019/009641 filed August
13, 2019, entitled ``T Cell Receptors Recognizing MHC Class II-
Restricted Mage-A3'' [HHS Reference No. E-230-2012-0-MX-16];
40. European Patent No. 3636665 issued June 29, 2022, entitled ``T
Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-EP-17];
a. Validated in: BE, DK, FR, DE, IT, NL, NO, ES, SE, CH and GB.
41. United States Patent Application No. 16/812,845 filed March 9,
2020, entitled ``T Cell Receptors Recognizing MHC Class II-Restricted
Mage-A3'' [HHS Reference No. E-230-2012-0-US-58];
42. Israeli Patent No. 274003 issued February 1, 2022, entitled ``T
Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-IL-59];
43. Japanese Patent Application No. 2020-114090 filed July 1, 2020,
entitled ``T Cell Receptors Recognizing MHC Class II-Restricted Mage-
A3'' [HHS Reference No. E-230-2012-0-JP-60];
44. Hong Kong Patent Application No. 42020016865.6 filed September
25, 2020, entitled ``T Cell Receptors Recognizing MHC Class II-
Restricted Mage-A3'' [HHS Reference No. E-230-2012-0-HK-61];
45. Korean Patent No. 2303166 issued September 10, 2021, entitled
``T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-KR-62];
46. Australian Patent Application No. 2021203746 filed June 7,
2021, entitled ``T Cell Receptors Recognizing MHC Class II-Restricted
Mage-A3'' [HHS Reference No. E-230-2012-0-AU-63];
47. Japanese Patent Application No. 2021-124003 filed July 29,
2021, entitled ``T Cell Receptors Recognizing MHC Class II-Restricted
Mage-A3'' [HHS Reference No. E-230-2012-0-JP-64];
48. Chinese Patent Application No. 202111028896.0 filed September
1, 2021, entitled ``T Cell Receptors Recognizing MHC Class II-
Restricted Mage-A3'' [HHS Reference No. E-230-2012-0-CN-65];
49. Korean Patent No. 2370307 issued February 28, 2022, entitled
``T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-KR-66];
50. Israeli Patent Application No. 286786 filed September 29, 2021,
entitled ``T Cell Receptors Recognizing MHC Class II-Restricted Mage-
A3'' [HHS Reference No. E-230-2012-0-IL-67];
51. Hong Kong Patent Application No. 42022051280.0 filed April 7,
2022, entitled ``T Cell Receptors Recognizing MHC Class II-Restricted
Mage-A3'' [HHS Reference No. E-230-2012-0-HK-68];
52. Korean Patent Application No. 10-2022-7006700 filed February
25, 2022, entitled ``T Cell Receptors Recognizing MHC Class II-
Restricted Mage-A3'' [HHS Reference No. E-230-2012-0-KR-69];
53. European Patent Application No. 22174521.9 filed May 20, 2022,
entitled
[[Page 80565]]
``T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3'' [HHS
Reference No. E-230-2012-0-EP-70]; and
54. United States Patent Application No. 17/936,006 filed September
28, 2022, entitled ``T Cell Receptors Recognizing MHC Class II-
Restricted Mage-A3'' [HHS Reference No. E-230-2012-0-US-82].
(and U.S. and foreign patent applications claiming priority to the
aforementioned applications)
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide, and
the field of use may be limited to the following:
``Development, manufacture and commercialization of allogeneic
Natural Killer (NK) cell therapy products engineered to express a
therapeutic T cell receptor claimed in the Licensed Patent Rights for
the treatment or prevention of cancer in humans.
Specifically excluded from this field of use are Natural Killer T
(NKT) cell therapy products engineered via viral and non-viral means
for the treatment of human cancers, wherein the NKT cell therapy
product contains at least 50% NKT cells.''
Intellectual Property Group A is primarily directed to isolated T
cell receptors (TCRs) reactive to mutated Kirsten rat sarcoma viral
oncogene homolog (KRAS), within the context of several human leukocyte
antigens (HLAs). Mutated KRAS, which plays a well-defined driver role
in oncogenesis, is expressed by a variety of human cancers, including
pancreatic, lung, endometrial, ovarian and prostate. Due to its
restricted expression in precancerous and cancerous cells, this antigen
may be targeted on mutant KRAS-expressing tumors with minimal normal
tissue toxicity.
Intellectual Property Group B is primarily directed to isolated
TCRs reactive to mutated tumor protein 53 (TP53 or P53), within the
context of several HLAs. P53 is the archetypal tumor suppressor gene
and the most frequently mutated gene in cancer. Contemporary estimates
suggest that >50% of all tumors carry mutations in P53. Because of its
prevalence in cancer and its restricted expression to precancerous and
cancerous cells, this antigen may be targeted on mutant P53-expressing
tumors with minimal normal tissue toxicity.
Intellectual Property Group C is primarily directed to isolated
TCRs reactive to the E7 oncoprotein of Human Papilloma Virus (HPV) type
16, within the context of HLA-A*02. E7 oncoprotein drives malignant
transformation in HPV-infected cells. Due to its specific and
constitutive expression in cancer cells, this antigen may be targeted
in HPV-positive malignancies, such as cervical carcinoma and
oropharyngeal carcinoma, with minimal normal tissue toxicity.
Intellectual Property Group D is primarily directed to isolated
TCRs reactive to Melanoma-associated antigens 3, 6 and 12 (MAGE-A3/A6/
A12), within the context of multiple HLAs. There are twelve MAGE-A
superfamily antigens designated A1-A12. These antigens are among the
most commonly expressed cancer testis antigens in a variety of tumors
and are associated with poor disease prognosis. They are not expressed
on normal cells other than non-MHC expressing germ cells of the testis,
which do not generate an immune response. Thus, these antigens may be
targeted on MAGE-A-expressing tumors with minimal normal tissue
toxicity.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: December 23, 2022.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2022-28404 Filed 12-29-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on December 30, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.